Ranibizumab as intravitreal injections is in clinical development for the treatment of diabetic retinopathy in both its proliferative and non-proliferative forms. Diabetic retinopathy, is a disease that affect the retinas and other parts of the inner eye. It is a chronic progressive condition of the retinal blood vessels due to prolonged raised blood glucose. When new blood vessels and scar tissue form on the retina causing bleeding within the eye and loss of vision, it is called proliferative diabetic retinopathy.
Ranibizumab has been designed to block a substance called vascular endothelial growth factor A (VEGF‑A), a protein that helps blood vessels grow and leak fluid and blood. By blocking this factor, ranibizumab reduces the growth of the blood vessels and controls the leakage and swelling in the retina. If licensed for diabetic retinopathy, ranibizumab has the potential to neutralise the retinal macular degeneration and reverse disease progression.
Clobetasol propionate ophthalmic nanoemulsion is in development for the treatment of post-operative pain or inflammation following cataract surgery. A cataract is a cloudy area in the lens, which can develop slowly and progress to general loss of transparency, which may lead to functional impairment and visual deterioration. Cataract surgery is the only effective treatment to improve or maintain vision, however, inflammation and pain are common difficulties following this treatment.